{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:43:34Z","timestamp":1788587014008,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Programmed death-ligand 1 (PD-L1) expression has been described in patients with malignant peritoneal mesothelioma (MPM), but treatment strategies utilising immune checkpoint inhibition are yet to be defined. Here, we examine levels of PD-L1 expression in MPM patients treated with systemic and\/or intraperitoneal chemotherapy using tissue from patient tumour biopsies or resections at multiple time points. We found the mean PD-L1 expression was higher in those with a germline mutation and\/or those with a higher somatic mutation burden. Moreover, PD-L1 expression was lower in patients who had received prior chemotherapy as compared to the treatment-naive cohort. Twenty patients who received chemotherapy, either systemic and\/or peritoneal, between PD-L1 measurements showed marked heterogeneity. Six (30%) patients demonstrated upregulation of PD-L1, while eight (40%) demonstrated downregulation. Heterogeneity in PD-L1 expression in MPM before and after cytotoxic therapies may present an additional consideration when initiating immune checkpoint inhibition in this rare and challenging disease.<\/jats:p>","DOI":"10.1038\/s41416-020-01130-x","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T02:02:24Z","timestamp":1603677744000},"page":"564-566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy"],"prefix":"10.1038","volume":"124","author":[{"given":"Michael G.","family":"White","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jefree J.","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaniv","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"Schuitevoerder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Vining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedy L.","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran K.","family":"Turaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver S.","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,26]]},"reference":[{"key":"1130_CR1","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","volume":"22","author":"JH Helm","year":"2015","unstructured":"Helm, J. H., Miura, J. T., Glenn, J. A., Marcus, R. K., Larrieux, G., Jayakrishnan, T. T. et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann. Surg. Oncol. 22, 1686\u20131693 (2015).","journal-title":"Ann. Surg. Oncol."},{"key":"1130_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2019.02.001","volume":"87","author":"DB Chapel","year":"2019","unstructured":"Chapel, D. B., Stewart, R., Furtado, L. V., Husain, A. N., Krausz, T. & Deftereos, G. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays. Hum. Pathol. 87, 11\u201317 (2019).","journal-title":"Hum. Pathol."},{"key":"1130_CR3","doi-asserted-by":"publisher","first-page":"S339","DOI":"10.1016\/j.jtho.2018.08.277","volume":"13","author":"A Desai","year":"2018","unstructured":"Desai, A., Karrison, T., Rose, B., Tan, Y., Hill, B., Pemberton, E. et al. OA08.03 Phase II Trial of pembrolizumab (NCT02399371) in previously-treated malignant mesothelioma (MM): final analysis. J. Thorac. Oncol. 13, S339 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"1130_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber, J. S., D\u2019Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375\u2013384 (2015).","journal-title":"Lancet Oncol."},{"key":"1130_CR5","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok, T. S. K., Wu, Y. L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393, 1819\u20131830 (2019).","journal-title":"Lancet"},{"key":"1130_CR6","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-14-3098","volume":"75","author":"J Peng","year":"2015","unstructured":"Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T. et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-kappab to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res. 75, 5034\u20135045 (2015).","journal-title":"Cancer Res."},{"key":"1130_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jmoldx.2016.07.012","volume":"19","author":"S Kadri","year":"2017","unstructured":"Kadri, S., Long, B. C., Mujacic, I., Zhen, C. J., Wurst, M. N., Sharma, S. et al. Clinical validation of a next-generation sequencing genomic oncology panel via cross-platform benchmarking against established amplicon sequencing assays. J. Mol. Diagn. 19, 43\u201356 (2017).","journal-title":"J. Mol. Diagn."},{"key":"1130_CR8","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","volume":"36","author":"V Panou","year":"2018","unstructured":"Panou, V., Gadiraju, M., Wolin, A., Weipert, C. M., Skarda, E., Husain, A. N. et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J. Clin. Oncol. 36, 2863\u20132871 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1130_CR9","doi-asserted-by":"publisher","first-page":"e1356146","DOI":"10.1080\/2162402X.2017.1356146","volume":"6","author":"S Terra","year":"2017","unstructured":"Terra, S., Mansfield, A. S., Dong, H., Peikert, T. & Roden, A. C. Temporal and spatial heterogeneity of programmed cell death 1-ligand 1 expression in malignant mesothelioma. Oncoimmunology 6, e1356146 (2017).","journal-title":"Oncoimmunology"},{"key":"1130_CR10","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/PAS.0000000000000780","volume":"41","author":"EA Dill","year":"2017","unstructured":"Dill, E. A., Gru, A. A., Atkins, K. A., Friedman, L. A., Moore, M. E., Bullock, T. N. et al. PD-L1 expression and intratumoral heterogeneity across breast cancer subtypes and stages: an assessment of 245 primary and 40 metastatic tumors. Am. J. Surg. Pathol. 41, 334\u2013342 (2017).","journal-title":"Am. J. Surg. Pathol."},{"key":"1130_CR11","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.2147\/OTT.S105862","volume":"9","author":"X Wang","year":"2016","unstructured":"Wang, X., Teng, F., Kong, L. & Yu, J. PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets Ther. 9, 5023\u20135039 (2016).","journal-title":"OncoTargets Ther."},{"key":"1130_CR12","doi-asserted-by":"publisher","first-page":"v931","DOI":"10.1093\/annonc\/mdz394.091","volume":"30","author":"S Popat","year":"2019","unstructured":"Popat, S., Curioni-Fontecedro, A., Polydoropoulou, V., Shah, R., O\u2019Brien, M., Pope, A., Fisher, P., Spicer, J. et al. A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann. Oncol. 30, v931 (2019).","journal-title":"Ann. Oncol."},{"key":"1130_CR13","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.1158\/1078-0432.CCR-16-2677","volume":"23","author":"DJ Messenheimer","year":"2017","unstructured":"Messenheimer, D. J., Jensen, S. M., Afentoulis, M. E., Wegmann, K. W., Feng, Z., Friedman, D. J. et al. Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40. Clin. Cancer Res. 23, 6165\u20136177 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1130_CR14","doi-asserted-by":"publisher","unstructured":"Bratman, S. V., Yang, C. S. Y., Iafolla, M. A. J., Liu, Z., Hansen A. R., Bedarad, P. et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat. Cancer. https:\/\/doi.org\/10.1038\/s43018-020-0096-5 (2020).","DOI":"10.1038\/s43018-020-0096-5"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01130-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01130-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01130-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:07:52Z","timestamp":1635206872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01130-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,26]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,2,2]]}},"alternative-id":["1130"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-01130-x","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,26]]},"assertion":[{"value":"7 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the University of Chicago Institutional Review Board. Consent was waived as a retrospective review of patient charts under IRB19-0793.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All informed consents were obtained. This report does not contain any individual person\u2019s information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The data that support the findings of this work are available from the corresponding author upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"H.L.K. reports personal fees from Aldeyra Therapeutics, personal fees and non-financial support from AstraZeneca, personal fees from Bayer, personal fees and non-financial support from Boehringer-Ingelheim, personal fees from Bristol Myers Squibb, personal fees from Kyowa, personal fees and non-financial support from Merck, personal fees and non-financial support from Paredox Therapeutics, personal fees from Inhibrx, personal fees from Deciphera, personal fees and non-financial support from Inventiva. The remaining authors have no competing interests to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"M.G.W. is supported through the National Institute of Health Kirschtein National Research Service (T32) Award. This work was supported using internal research fund through the University of Chicago, Department of Surgical Oncology.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}